Bitolterol

From Wikipedia, the free encyclopedia
  (Redirected from Bitolterol mesylate)
Jump to: navigation, search
Bitolterol
Bitolterol.svg
Clinical data
AHFS/Drugs.com Micromedex Detailed Consumer Information
MedlinePlus a601236
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C28H31NO5
Molar mass 461.549 g/mol
3D model (Jmol)
Chirality Racemic mixture

Bitolterol mesylate (Tornalate) is a short-acting β2 adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma[1][2] and COPD.[3][4][5] In these disorders there is a narrowing of the airways (bronchi and their ramifications) that carry air to the lungs. Muscle spasm and inflammation within the bronchi get worse this narrowing. Bitolterol relaxes the smooth muscles present continuously around the bronchi and bronchioles facilitating the flow of air through them.

Colterol

Bitolterol is a prodrug of colterol.[6][7] It has a rapid onset of action (2–5 minutes) and may last up to 6–8 hours.[8] The drug, alone or in co-administration with theophylline, doesn't show cardiotoxic effect.[9]

The U.S. Food and Drug Administration (FDA) approved bitolterol in December 1984. The drug was withdrawn from the market by Élan Pharmaceuticals in 2001.

References[edit]

  1. ^ Nathan RA, Bodman SF, Storms WW, Mingo TS (June 1986). "Bitolterol mesylate aerosol in adults with steroid-dependent asthma: a comparison with isoproterenol hydrochloride aerosol". Ann Allergy. 56 (6): 494–9. PMID 3717716. 
  2. ^ Nathan RA, Bernstein IL, Bronsky EA, Bush RK, Chervinsky P, Condemi JJ, Dockhorn RJ, Pinnas JL, Repsher LH (May 1987). "Comparison of the bronchodilator effects of nebulized bitolterol mesylate and isoproterenol hydrochloride in steroid-dependent asthma". J. Allergy Clin. Immunol. 79 (5): 822–9. doi:10.1016/0091-6749(87)90216-8. PMID 3571773. 
  3. ^ Friedel HA; Brogden RN (1988). "Bitolterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible obstructive airways disease". Drugs. 35: 22–41. doi:10.2165/00003495-198835010-00002. 
  4. ^ Anderson, JR.; Groves, PM.; Schwartz, GE. (Jan 1979). "Early Career Awards for 1978 (John Robert Anderson, Philip M. Groves, Gary E. Schwartz).". Am Psychol. 34 (1): 69–79. PMID 396832. 
  5. ^ Petty, TL.; Scoggin, CH.; Rollins, DR.; Repsher, LH. (Sep 1984). "Bitolterol compared to isoproterenol in advanced chronic obstructive pulmonary disease.". Chest. 86 (3): 404–8. doi:10.1378/chest.86.3.404. PMID 6380974. 
  6. ^ Walker, Susannah B.; Kradjan, Wayne A.; Bierman, C. Warren (6 May 1985). "Bitolterol Mesylate: A Beta-adrenergic Agent; Chemistry, Pharmacokinetics, Pharmacodynamics, Adverse Effects and Clinical Efficacy in Asthma". Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 5 (3): 127–137. doi:10.1002/j.1875-9114.1985.tb03410.x. PMID 3895171. 
  7. ^ "ChEBI: Bitolterol". Chemical Entities of Biological Interest. Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD, UK. Retrieved 27 March 2016. 
  8. ^ Kass, I.; Mingo, TS. (Aug 1980). "Bitolterol mesylate (WIN 32784) aerosol. A new long-acting bronchodilator with reduced chronotropic effects.". Chest. 78 (2): 283–7. doi:10.1378/chest.78.2.283. PMID 6995040. 
  9. ^ Kemp, JP.; Chervinsky, P.; Orgel, HA.; Meltzer, EO.; Noyes, JH.; Mingo, TS. (Jan 1984). "Concomitant bitolterol mesylate aerosol and theophylline for asthma therapy, with 24 hr electrocardiographic monitoring.". J Allergy Clin Immunol. 73 (1 Pt 1): 32–43. doi:10.1016/0091-6749(84)90481-0. PMID 6693665.